Health benefit plan; prohibit the terms of being based on certain information.
Summary
House Bill 1607 would prohibit pharmacy benefit managers (PBMs), insurers, and third-party administrators from directly or indirectly setting, changing, implementing, or conditioning the terms of a health benefit plan based on information about the availability or amount of financial assistance or product assistance for a prescription drug. The restriction applies to plan design generally, including benefit design, and is aimed at preventing coverage decisions from being influenced by whether a patient can obtain outside assistance to pay for a medication.
The bill would add this prohibition as a new section in Chapter 21 of Title 73 of the Mississippi Code, with an effective date of July 1, 2025. In practical terms, it would limit how health plans and their administrators may use copay assistance, manufacturer support, or similar drug-related assistance information when structuring prescription drug benefits or other plan terms.
Impact
HB 1607 would create a new statutory restriction on PBMs, insurers, and third-party administrators in Mississippi’s insurance code. It would not establish a new benefit program or mandate coverage of specific drugs, but it would regulate the criteria used to design or administer health benefit plans, especially prescription drug benefits. The bill could affect how plans handle copay accumulator or maximizer practices and how they respond to manufacturer assistance programs, potentially changing cost-sharing administration for patients and plan sponsors.
Sentiment
The available context suggests the bill is framed as a consumer-protection and transparency measure, with no recorded committee debate or vote history provided. Its caption and text indicate a policy goal of preventing health plan terms from being influenced by the presence of financial assistance for prescription drugs, which generally aligns with efforts to reduce patient cost burdens. Because there are no transcripts or votes, there is no documented opposition or support in the provided materials, but the bill’s subject matter suggests it would likely be viewed favorably by patient advocates and scrutinized by insurers and PBMs.
Contention
The main point of contention would likely be whether prohibiting plan terms from considering drug assistance information interferes with PBM and insurer benefit design or raises costs for plans and premiums. Supporters would likely argue that the bill prevents unfair treatment of patients who rely on copay assistance and preserves access to needed medications. Opponents, if any, would likely come from insurers, PBMs, or employer plan administrators concerned about administrative flexibility, cost containment, and the interaction with existing drug pricing and benefit management practices.